A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer Interventions:   Drug: Trastuzumab deruxtecan;   Drug: Durvalumab;   Drug: Paclitaxel;   Drug: Capivasertib;   Drug: Anastrozole;   Drug: Fulvestrant;   Drug: Capecitabine Sponsors:   AstraZeneca;   Daiichi Sankyo Company, Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials